News Release Details

A.P. Pharma to Hold 2007 Fourth Quarter Financial Results Conference Call March 13

03/10/2008 |

REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 10, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2007 fourth quarter financial results before the market opens on Thursday, March 13, 2008.

Company executives will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, March 13, 2008 to discuss the financial results, provide a business update and answer questions.

To participate in the live call by telephone, please dial (888) 803-8275 from the U.S., and for international callers, please dial (706) 634-1287. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 38668203.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the Company's Web site for 30 days.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications. For further information visit the Company's web site at www.appharma.com.

CONTACT: Company Contact:
A.P. Pharma, Inc.
Gregory Turnbull
President and Chief Executive Officer
650-366-2626
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Don Markley or Bruce Voss, 310-691-7100
dmarkley@lhai.com
bvoss@lhai.com
SOURCE: A.P. Pharma, Inc.

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.